Trading-news Biopharma Stock List Update: Incy, Sppi, Staa, Trgt, Ista, Jazz

Stock in focus today 7/21/09:

INCY (NASDAQ) up 15% :

Incyte Reaches Agreement with FDA on a Special Protocol Assessment for INCB18424 in Myelofibrosis

SPPI (NASDAQ) up 12,5%:

FDA Designates Fast Track Status for Apaziquone (EOquin®) for Bladder Cancer

STAA (NASDAQ) up 9%:

Review of STAAR's application for the Visian Toric Implantable Collamer Lens by FDA to resume

TRGT (NASDAQ)  we are selling the stock at 8,7 usd with 60% gain

ISTA (NASDAQ) a long term strong play,  at 4,75 usd

JAZZ (NASDAQ) up 13% to 4,5 usd

We sold at open IDIX (NASDAQ), published study results for IDX 184 which was not as good as hoped

TICKER                       BUY AREA      QUOTE NOW     POSITION            DRIVER

IDIX (NASDAQ)        USD  4,44            4,2 SOLD(-5%)

SNTS (NASDAQ)     USD   2,81             3     LONG TERM     FDA REVIEW Zegerid BY DECEMBER

BFRM (NASDAQ)        USD   2,85           2            LONG TERM OVERSOLD CONDITIONS

OCLS (NASDAQ) USD 2,85     2,6          LONG TERM    MORE UPSIDE

TRGT (NASDAQ) USD 5,5          8,7 SOLD(+60%) 

OREX (NASDAQ) USD 5,35     6,45 SOLD(+20%)  

FOLD (NASADQ) USD 10           10,5  LONG TERM     PLICERA, AMIGAL STRONG  CONSENSUS

SOMX (NASDAQ) USD 1,10       1,38   SOLD (+25%)    

DDSS (NASDAQ)  USD 2,65    1,9      SHORT TERM   TRAZODONE FDA  PDUFA 7/18/09

XNPT (NASDAQ)  USD 21,85      20    LONG TERM    XP19986  POSITIVE TRIAL 6/30/09

VNDA (NASDAQ) 12,1                 13        REBUYING      FANAT APPROVED 5/6/09

CYTR (NASDAQ)   USD 1,02      1,2        LONG TERM    STRONG CONSENSUS

JAZZ (NASDAQ)    USD 4,95     4,5    LONG TERM         STRONG CONSENSUS

PARD (NASDAQ)    USD 5          5,9      PROFIT TAKING(+18%)     

PARD (NASDAQ) USD 6,6 rebought 7/2    6,9  LONG TERM       STRONG CONSENSUS

INCY (NASDAQ) USD 3,5         4,6    LONG TERM            STRONG CONSENSUS

ISTA (NASDAQ) USD 4,1         4,7       LONG TERM          BEPREVE FDA  PDUFA  9/12/09

JAV (AMEX)      USD 1,3          1,55       LONG TERM         STRONG CONSENSUS

SLXP (NASDAQ) USD 9,9        11,5  LONG TERM  STRONG CONSENSUS FDA PDUFA 9/9/09

MAPP (NASDAQ) USD 11,3       10  REBUYING LONG TERM STRONG CONSENSUS 

ARYX (NASDAQ) USD            4,5       SOLD 2,5 (-45%)

ARRY (NASDAQ) USD 3,1      3,2    LONG TERM           CLINICAL TRIAL 7/8/09

GTXI (NASDAQ)   USD 9,5      8,8     LONG TERM         FDA PDUFA 10/30/09

UTHR (NASDAQ) USD 84         86,4 LONG TERM        FDA PDUFA 7/30/09

NGSX (NASDAQ) USD 6,4      7,6 LONG TERM        FDA PDUFA 8/16/09

VICL (NASDAQ)  USD 3             2,7    LONG TERM      SWINE FLU

STAA (NASDAQ)  USD 3,3        2,45 LONG TERM   FDA CLEARENCE FOR Epiphany(TM)

ALTH (NASDAQ)  7,9               7,7   LONG TERM          FDA PDUFA 9/24/09

AMAG (NASDAQ) 52,8        50,6  LONG TERM        FDA APPROVES FERAHEME 6/30/09

XOMA (NASDAQ) 1,2    0,77  LONG TERM  OVERSOLD

HEB (AMEX)    3,3(5%OF CAPITAL)  2,25 SOLD(-35%)                                

HEB (AMEX) was rebought after 100% gain (see old posts)

MRNA (NASDAQ)  3,3            1,5      LONG TERM      OVERSOLD

RIGL (NASDAQ) USD 10           14,4     LONG TERM     STRONG CONSENSUS

MITI (NASDAQ) USD 6              5,05       LONG TERM      OVERSOLD

MNKD (NASDAQ) USD 8,3         7,95    SOLD(-4%)    

SVNT (NASDAQ) USD 7,10        13       SOLD(+90%)

NPSP (NASDAQ) 3,1 USD        4,75     SOLD(+50%)

SCLN (NASDAQ) 2,25 USD        2,7     SOLD (+20%)  LONG TERM ZADAXIN SALES

MAPP (NASDAQ) 8 USD  (posts from 5/26)  PROFIT TAKED(+45%)   LEVADEX

VNDA (NASDAQ) 8 USD (see old post 5/8)  PROFIT TAKED(+80%)     FANAT

CLDA (NASDAQ) 15,7 USD         9,5  LONG TERM   OVERSOLD

CTIC (NASDAQ) 2,10 USD        1,39 SOLD (-35%)

ANPI (NASDAQ) 2 USD           1,39 SOLD(-30%)

MEDX (NASDAQ) 7,5 USD   8,7  PROFIT TAKING(+20%)  LTERM RECENT PRODUCTS RESULTS

MNTA (NASDAQ) 8,9 USD      11,2   LONG TERM   STRONG CONSENSUS

ACAD (NASDAQ) 2,6 USD     2,4       LONG TERM  CLINICAL DATA  3 Q.

ACOR (NASDAQ) 24 USD   23,6   LONG TERM FAMPRIDINE-SR, FDA PDUFA 10/22/09

BDSI (NASDAQ)                           PROFIT TAKED 6,3  (+18%)  

BDSI (NASDAQ)  6,6 rebought   5,4      SHORT TERM    ONSOLIS APPROVED BY FDA

DNDN (NASDAQ)  22 USD (see old post 4/27) 23,1  LONG TERM  PROVENGE

SPPI (NASDAQ)  4 USD (see ols post 5/12)    6/12 PROFIT TAKING (+35%)

SPPI (NASDAQ)  5,85 USD         7,4     PROFIT TAKING(+28%) 

SPPI (NASDAQ)  6,5 USD rebought 7/2  6,6  LT  ZEVALIN FDA PDUFA  09/07/09

FUSILEV PDUFA 08/10/09